Get the Stockscreener App
0.00
100.00%
-106.91
After Hours:
106.94
106.94
+
Verona Pharma Plc Adr stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
See More
Previous Close:
$106.91
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$9.19B
Revenue:
-
Net Income/Loss:
$-153.72M
P/E Ratio:
0.00
EPS:
-2
Net Cash Flow:
$-103.81M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$106.93
Verona Pharma Plc Adr Stock (VRNA) Company Profile
Name
Verona Pharma Plc Adr
Sector
Industry
Phone
011-44-0-2032834200
Address
3 MORE LONDON RIVERSIDE, LONDON
Compare VRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRNA
Verona Pharma Plc Adr
|
0.00 | 9.19B | 0 | -153.72M | -103.81M | -2.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-01-25 | Initiated | Wolfe Research | Outperform |
| Apr-28-25 | Initiated | TD Cowen | Buy |
| Apr-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Oct-03-24 | Initiated | Wells Fargo | Overweight |
| May-22-23 | Resumed | Jefferies | Buy |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Aug-26-22 | Initiated | Piper Sandler | Overweight |
| Sep-13-21 | Initiated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Jefferies | Buy |
| Aug-10-20 | Initiated | Canaccord Genuity | Buy |
| Apr-18-19 | Initiated | BTIG Research | Buy |
View All
Verona Pharma Plc Adr Stock (VRNA) Latest News
Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Receives Average Rating of “Hold” from Brokerages - Defense World
US Bancorp DE Has $748,000 Holdings in Verona Pharma PLC American Depositary Share $VRNA - Defense World
VRNA: Cantor Fitzgerald Maintains Overweight Rating with $100 PT - GuruFocus
Verona Pharma plc (VRNA)’s Shareholders Authorizes the $10 Billion Acquisition of Verona Pharma plc (VRNA); Nasdaq Trading to Suspend - Yahoo Finance
Merck completes acquisition of Verona Pharma; VRNA shares delisted from Nasdaq - Investing.com
BioSpace Announces Inaugural 40 Under 40 Winners (2025-10-07) - Seeking Alpha
Verona Pharma (VRNA): A Fresh Look at Current Valuation and Market Expectations - Sahm
Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales - Sahm
Verona Pharma stock hits all-time high at 106.91 USD By Investing.com - Investing.com Canada
Court approves MSD’s $10 billion acquisition of Verona Pharma - Investing.com
Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales - Benzinga
Verona Pharma stock hits all-time high at 106.91 USD - Investing.com
Is There Still Opportunity in Verona Pharma After Ohtuvayre Approval and 246% Price Surge? - Sahm
VRNA Quantitative Stock Analysis - Nasdaq
Verona Pharma stock reaches all-time high at 106.75 USD By Investing.com - Investing.com Nigeria
Verona Pharma stock reaches all-time high at 106.75 USD - Investing.com India
Verona Pharma shareholders approve $10 billion Merck acquisition - Investing.com
AstraZeneca Asthma Drug Fails COPD Study for a Second Time - Bloomberg.com
Verona Pharma stock hits all-time high at 106.45 USD - Investing.com India
Verona Pharma stock hits all-time high at 106.45 USD By Investing.com - Investing.com Canada
Verona Pharma Extends Severance Benefits Amid Merck Deal - The Globe and Mail
Invesco Ltd. Makes New Investment in Verona Pharma PLC American Depositary Share $VRNA - Defense World
Verona Pharma stock hits all-time high at 106.19 USD By Investing.com - Investing.com Australia
Verona Pharma stock hits all-time high at 106.19 USD - Investing.com
Merck Taps US Investment-Grade Bond Market for Verona Purchase - Bloomberg.com
Verona Pharma stock hits all-time high at 105.86 USD By Investing.com - Investing.com Australia
Verona Pharma stock hits all-time high at 105.86 USD - Investing.com
TRAILBLAZERS TAKE THE STAGE: PM360 TO CROWN LIFE SCIENCES' BRIGHTEST, SEPTEMBER 30 - Seeking Alpha
Verona Pharma (VRNA) Skyrockets 20.6% on $10-Billion Merger Deal with Merck - MSN
Verona Pharma : Notice of Meetings and Proxy Statement in connection with proposed acquisition of Verona Pharma - MarketScreener
Verona Pharma stock reaches all-time high at 105.54 USD By Investing.com - Investing.com Nigeria
Verona Pharma stock reaches all-time high at 105.54 USD - Investing.com
Merck to Acquire Verona Pharma in $10 Billion Deal to Expand Respiratory Drug Portfolio - MSN
Verona Pharma ADR earnings beat by $0.11, revenue topped estimates - Investing.com Nigeria
Verona Pharma CFO Hahn sells $2.75 million in shares By Investing.com - Investing.com India
Verona Pharma (VRNA) director Ackermann sells $24k in shares - Investing.com
Verona Pharma CFO Hahn sells $2.75 million in shares - Investing.com
Verona Pharma director Cunningham sells shares for $142,057 By Investing.com - Investing.com South Africa
Verona Pharma (VRNA) director Deschamps sells $124,391 in shares - Investing.com India
Verona Pharma director Cunningham sells shares for $142,057 - Investing.com India
VERONA PHARMA PLCADR: Quantitative Momentum Investor Model Ratings - AInvest
Investing $2,000 in Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth Nearly $135,000 Today - The Globe and Mail
Verona Pharma stock hits all-time high at 105.31 USD By Investing.com - Investing.com Nigeria
Verona Pharma stock hits all-time high at 105.31 USD - Investing.com
Verona Pharma Plc ADR’s Shares Reel: 69.24% Quarterly Revenue Decline Amid 8.93B Market Cap - investchronicle.com
Verona Pharma stock reaches all-time high at 105.0 USD By Investing.com - Investing.com Australia
Verona Pharma Plc Adr Stock (VRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):